32 Biosciences revealed its plan to launch a $40 million Series A at this year’s J.P Morgan Healthcare conference, to advance ...

Join journalists from around the world covering the premier conference in genetics and genomics on March 10-14, 2026, in ...

Co-founded by Jennifer Doudna and Fyodor Urnov, the company intends to simultaneously develop many gene editing treatments for rare conditions by using the agency’s “plausible mechanism” pathway.

Union Minister Jitendra Singh highlights India's shift to genomics and personalised medicine, addressing challenges in ...

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespect ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

Researchers at University of California San Diego School of Medicine have led the first clinical trial in the world to show ...

Hims & Hers Health, Inc. is rated a Buy with strong subscriber growth and rising revenue per subscriber. Learn more about ...

Emphasising that early detection and affordability are the two biggest challenges in addressing genetic and rare diseases, ...

Discovery could redirect drug development for disease affecting 6.7 million Americans The two AMPKα isoforms can have ...

According to Dr. Jennifer Levin Carter, MD, founder and CEO of Medzown, the concept of personalized medicine shifted from a ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in ...